Valvular & structural heart diseaseCohort study
Early Outcomes of Real-World Transcatheter Tricuspid Valve Replacement
- Retrospective cohort study
- multicentre
- 12 centres in 5 European countries
- consecutive patients
Authors' conclusion
TR elimination following TTVR in a real-world setting was associated with significant symptom and end-organ functional improvement.
Study context
- Population
- Patients with severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system since European approval (October 2023 to February 2025)
- Participants
- 176 patients
- Outcome
- Real-world safety and efficacy (clinical outcomes)
- Follow-up
- 30-day follow-up
Main finding
As reported in the abstract
Severe or greater TR reduced to mild or none · median follow-up 30 days (IQR: 2 days)
Severe or greater TR reduced to mild or none
126 of 128 patients (98.4%; P < 0.001)
Observational data: associations, not effects.
Further findings
Clinical failure at 1-month follow-up: predictor
| Comparison | OR (95% CI) | P value | |
|---|---|---|---|
| Moderate or severe right ventricular dysfunction · independent predictor | 3.60 (1.39–9.32) | P = 0.008 | |
| 0.10.31310Odds ratio (log scale) |
NYHA class I or II · 1 month
- NYHA class I or II at baseline
- 20.2% (28 of 138)
- NYHA class I or II at 1 month
- 79.7% (110 of 138; P) at 1 month (P < 0.001)
eGFR, baseline vs follow-up
- eGFR baseline vs follow-up
- 47.0 ± 19.9 mL/min/1.73 m² vs 53.7 ± 23.3 mL/min/1.73 m² [P < 0.001]
Bilirubin, baseline vs follow-up
- Bilirubin baseline vs follow-up
- 14.2 ± 8.8 μmol/L vs 11.0 ± 9.8 μmol/L [P < 0.001]
Massive or torrential TR at baseline: NYHA improved vs stable or worsening
- Massive or torrential TR at baseline, improved vs stable or worsening NYHA class
- 75 of 98 [76.5%] vs 20 of 40 [50.0%]; P = 0.004
Safety
Permanent pacemaker implantation (pacemaker-naive)
| Comparison | OR (95% CI) | P value | |
|---|---|---|---|
| Conduction disturbances at baseline | 4.53 (1.73–11.82) | P = 0.002 | |
| 0.050.21520Odds ratio (log scale) |
- Permanent pacemaker implantation (pacemaker-naive) — Permanent pacemaker implantation required
- 21 of 111 pacemaker-naive patients (18.9%)
Original publication
Early Outcomes of Real-World Transcatheter Tricuspid Valve Replacement. JACC Cardiovasc Interv. Published 25 June 2025. doi:10.1016/j.jcin.2025.06.002
Summarised from the published abstract; every number is checked against it